Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Moodys
Chubb
Harvard Business School
Mallinckrodt
Cerilliant
Healthtrust
Chinese Patent Office
US Army
Federal Trade Commission

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,637,553

« Back to Dashboard

Which drugs does patent 8,637,553 protect, and when does it expire?


Patent 8,637,553 protects STIVARGA and is included in one NDA. There has been one Paragraph IV challenge on Stivarga.

This patent has sixty patent family members in thirty-eight countries.

Summary for Patent: 8,637,553

Title:Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
Abstract: A compound of Formula (I): ##STR00001## salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by raf, VEGFR, PDGFR, p38 and flt-3.
Inventor(s): Boyer; Stephen (Hilden, DE), Dumas; Jacques (Bethany, CT), Riedl; Bernd (Wuppertal, DE), Wilhelm; Scott (Orange, CT)
Assignee: Bayer Healthcare LLC (Tarrytown, NY)
Application Number:10/895,985
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Bayer HlthcareSTIVARGAregorafenibTABLET;ORAL203085-001Sep 27, 2012RXYesYes► Subscribe► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,637,553

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1663978► Subscribe
New Zealand580384► Subscribe
New Zealand544920► Subscribe
Norway335323► Subscribe
Norway20060870► Subscribe
Malaysia142799► Subscribe
Mexico2007014726► Subscribe
MontenegroP38308► Subscribe
Morocco27946► Subscribe
Luxembourg92300► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Merck
Baxter
QuintilesIMS
Cerilliant
Chubb
Cipla
Medtronic
Citi
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot